<DOC>
	<DOCNO>NCT00892450</DOCNO>
	<brief_summary>The purpose research study investigate cognitive ( think , memory , knowledge , intelligence ) side effect two medication commonly use treat overactive bladder ( OAB ) symptom veteran patient Parkinson 's disease ( PD ) see Philadelphia PADRECC .</brief_summary>
	<brief_title>Anticholinergic Therapy Overactive Bladder Parkinson 's Disease</brief_title>
	<detailed_description>This study double-blinded cross-over clinical trial design ass prevalence cognitive effect , efficacy , effect quality life ( QOL ) two anticholinergic medication commonly use treatment overactive bladder ( OAB ) : oxybutynin darifenacin . This do use well-established validated computer-based cognitive battery . Secondary endpoint assess efficacy anticholinergic therapy symptom OAB via QOL questionnaire participant urinary diary .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Diagnosis idiopathic PD ( ICD9=332.0 ) MMSE 24 , able give inform consent complete questionnaire void diary . Urological workup within 3 month enrollment : Rule treatable cause urinary symptom Urinalysis ( UA ) Postvoid residual ultrasound ( PVR ) Urinary cytology Documented symptom OAB screen 3day void diary : Average 1 urgency episode / 24 hour , Average 8 micturition / 24 hour Subjective complaint symptoms 3 month Exposure anticholinergic antispasmodic within last 4 week ( among : atropine , tolterodine , benztropine , trihexyphenidyl , dicyclomine , hyoscyamine , scopolamine ) Exposure drug know effect cognition ( i.e . opioids , benzodiazepine sedate antihistamine ) within last week Exposure drug contraindicate caution use 2 study medication ( drug also use cytochrome P450 enzyme , primarily CYP3A4 ) . These include : ketoconazole , itraconazole , miconazole , erythromycin , clarithromycin , ritonavir , nelfinavir , nefazodone , flecainide , thioridazine tricyclic antidepressant . Nonpharmacological treatment OAB within last 4 week ( example : biofeedback , physical therapy , acupuncture ) Uncontrolled narrow angle glaucoma History gastric urinary retention / dysmotility ( ulcerative colitis , myasthenia gravis severe constipation ) History hepatic renal impairment History severe gastroesophageal reflux disease and/or use bisphosphonates , patient risk esophagitis Previous exposure anticholinergic OAB symptom result side effect cause cessation medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Overactive bladder symptom</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>darifenacin</keyword>
	<keyword>oxybutynin</keyword>
	<keyword>cognition</keyword>
</DOC>